ZA202407659B - Compositions having improved bioavailability of therapeutics and uses thereof - Google Patents
Compositions having improved bioavailability of therapeutics and uses thereofInfo
- Publication number
- ZA202407659B ZA202407659B ZA2024/07659A ZA202407659A ZA202407659B ZA 202407659 B ZA202407659 B ZA 202407659B ZA 2024/07659 A ZA2024/07659 A ZA 2024/07659A ZA 202407659 A ZA202407659 A ZA 202407659A ZA 202407659 B ZA202407659 B ZA 202407659B
- Authority
- ZA
- South Africa
- Prior art keywords
- disclosed
- present specification
- compositions
- therapeutics
- fibrates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269330P | 2022-03-14 | 2022-03-14 | |
| PCT/EP2022/058180 WO2022207580A2 (en) | 2021-03-27 | 2022-03-28 | Compositions having improved bioavailability of therapeutics |
| PCT/EP2023/056506 WO2023174948A2 (en) | 2022-03-14 | 2023-03-14 | Compositions having improved bioavailability of therapeutics and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202407659B true ZA202407659B (en) | 2026-01-28 |
Family
ID=85571360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/07659A ZA202407659B (en) | 2022-03-14 | 2024-10-09 | Compositions having improved bioavailability of therapeutics and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4493151A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025509680A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023233811A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3245873A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL315617A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023174948A2 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA202407659B (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4784247A1 (en) * | 2023-09-28 | 2026-08-05 | The Regents Of The University Of California | Methods and compositions of treating age-related conditions |
| WO2025093572A1 (en) * | 2023-10-29 | 2025-05-08 | TRx Biosciences Limited | Solid dispersion compositions and uses thereof |
| WO2026053168A1 (en) * | 2024-09-06 | 2026-03-12 | Graviton Bioscience Bv | Amorphous forms of a rock2 inhibitor and formulations thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
| US5885486A (en) * | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US20020028813A1 (en) * | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| JP5758630B2 (ja) * | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Parp阻害剤としてのピリダジノン誘導体 |
| EP2346495B2 (en) * | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmaceutical formulation 514 |
| CN102307576A (zh) * | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
| CN101507707B (zh) * | 2009-04-08 | 2011-01-19 | 邓菊娟 | 一种盐酸法舒地尔脂微球制剂及其制备方法 |
| CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| CN102813639B (zh) * | 2011-06-08 | 2014-04-30 | 中国疾病预防控制中心寄生虫病预防控制所 | 甲苯达唑软胶囊剂 |
| US9073944B2 (en) * | 2012-02-21 | 2015-07-07 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| AU2014360537B2 (en) * | 2013-12-04 | 2017-09-07 | Gilead Sciences, Inc. | Methods for treating cancers |
| ES2975417T3 (es) * | 2017-03-03 | 2024-07-05 | Inspirna Inc | Formulaciones con estabilidad mejorada |
| WO2020079706A1 (en) * | 2018-10-15 | 2020-04-23 | Cipla Limited | Pharmaceutical formulation |
| WO2020217235A1 (en) * | 2019-04-24 | 2020-10-29 | Aizant Drug Research Solutions Private Limited | Solid dosage form of dasatinib |
| CN113546045B (zh) * | 2021-08-18 | 2022-11-11 | 浙江大学 | 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用 |
-
2023
- 2023-03-14 AU AU2023233811A patent/AU2023233811A1/en active Pending
- 2023-03-14 CA CA3245873A patent/CA3245873A1/en active Pending
- 2023-03-14 JP JP2024555003A patent/JP2025509680A/ja active Pending
- 2023-03-14 WO PCT/EP2023/056506 patent/WO2023174948A2/en not_active Ceased
- 2023-03-14 EP EP23710760.2A patent/EP4493151A2/en active Pending
- 2023-03-14 IL IL315617A patent/IL315617A/en unknown
-
2024
- 2024-10-09 ZA ZA2024/07659A patent/ZA202407659B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL315617A (en) | 2024-11-01 |
| CA3245873A1 (en) | 2023-09-21 |
| EP4493151A2 (en) | 2025-01-22 |
| WO2023174948A2 (en) | 2023-09-21 |
| AU2023233811A1 (en) | 2024-09-19 |
| WO2023174948A3 (en) | 2023-10-26 |
| JP2025509680A (ja) | 2025-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022207580A3 (en) | Compositions having improved bioavailability of therapeutics | |
| WO2023174948A3 (en) | Compositions having improved bioavailability of therapeutics and uses thereof | |
| NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| EA201290108A1 (ru) | Составы в виде везикул | |
| MX2013006598A (es) | Inhibidores de la amida hidrolasa de acidos grasos (faah). | |
| UA102478C2 (en) | Capsule composition | |
| GB2459809A (en) | Fatty acid formulations and methods of use thereof | |
| PH12012501054A1 (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| IN2014DN08449A (cg-RX-API-DMAC10.html) | ||
| BR112013020167A2 (pt) | melhoradores de permeação para formulações tópicas | |
| CN104039303A (zh) | 含有高浓度的咖啡因和烟酰胺的化妆品组合物 | |
| ATE413865T1 (de) | Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür | |
| MX2009012782A (es) | Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados. | |
| MX2009009838A (es) | Esteres de acidos grasos de glucocorticoides como agentes antiinflamatorios y anti-cancer. | |
| EA201590591A1 (ru) | Способ приготовления геля на основе полифенолов гранатовой кожуры для лечения воспалительных заболеваний в гинекологии | |
| JO2324B1 (en) | Pharmaceutical compounds for topical oral use | |
| EP4470621A3 (en) | Use of sodium alkyl sulfate | |
| CA2910103C (en) | Topical composition for enhancing skin sensitivity and use thereof | |
| PH12021550391A1 (en) | Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient | |
| MX351222B (es) | Composición transparente o translúcida. | |
| MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
| CN102271652B (zh) | 含有共轭亚油酸的纳米水乳液组合物 | |
| CR20230257A (es) | Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d | |
| CA2865557C (fr) | Formulation gelifiante a base de gluconate de calcium | |
| BR112022017963A2 (pt) | Composição farmacêutica para prevenção ou tratamento de esteato-hepatite não alcoólica |